SCHEMBL6549004

SCHEMBL6549004

CCON=C(C)c1ccc(COc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HTT P42858 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PPARG P37231 2/20 0.34
PPARA Q07869 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 3/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CCR5 P51681 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PTBP1 P26599 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549405 0.94 NPC1 (0.35) NPC1RAB9AHTTHRH3SMN1; SMN2
SCHEMBL6549656 0.91 ESR1 (0.36) NPC1RAB9AHTTPPARGPPARA
SCHEMBL6547273 0.91 NPC1 (0.44) NPC1RAB9AHTTKDM4EPPARG
SCHEMBL6548842 0.90 HRH3 (0.43) HTTHRH3MAOAMAOBMAPT
SCHEMBL6547677 0.90 SMN1; SMN2 (0.33) NPC1RAB9AHTTPPARGPPARA
SCHEMBL6549002 0.89 HTT (0.33) NPC1RAB9AHTTPPARGPPARA
SCHEMBL6549867 0.88 HTT (0.36) HTTKDM4EPPARGHRH3MAOA
SCHEMBL6548809 0.87 HTT (0.33) NPC1RAB9AHTTHRH3SMN1; SMN2
SCHEMBL6547607 0.87 HTT (0.33) HTTHRH3MAOAMAOBMAPT
SCHEMBL6547864 0.87 HTT (0.39) NPC1RAB9AHTTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 NPC1 1404/4885RAB9A 2309/4885HTT 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.